Available Brands
Did you find this information helpful?
Author Details
Written By
Prakruthi Madhusudan
MSc Bioinformatics

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 12 Nov 2026 | 04:45 PM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
ABIRATERONE ACETATE
Last updated on 12 Nov 2026 | 04:45 PM (IST)
ABIRATERONE ACETATE
Molecule Overview
Abiraterone acetate is an oral medicine that lowers the body's production of androgens (male hormones) that can fuel prostate cancer growth. It belongs to a class of medicines called CYP17 inhibitors (androgen biosynthesis inhibitors), used for advanced prostate cancer. It is a prescription-only medicine, always given together with a steroid (prednisone).
Medical Classification
Therapeutic Class: Anti-cancer (oncology) hormonal therapy.
Pharmacological Class: CYP17 (17alpha-hydroxylase/C17,20-lyase) inhibitor.
Drug Family: Androgen biosynthesis inhibitors.
ATC Classification: L02BX03 (Abiraterone).
Conditions Treated
Approved: Metastatic castration-resistant prostate cancer (in combination with prednisone, both before and after chemotherapy), and metastatic high-risk castration-sensitive prostate cancer (in combination with prednisone and ongoing testosterone-suppressing therapy).
Commonly used for: Men with advanced prostate cancer that continues to progress despite standard hormone-lowering therapy.
Off-label use (only under medical guidance): Occasionally explored in earlier-stage or other hormone-sensitive prostate cancer settings within research protocols.
Available Strengths & Dosage Forms
● Oral tablets: commonly available as 250 mg and 500 mg tablets.
How the Molecule Works
Testosterone and other androgens can fuel prostate cancer growth, and are produced not only in the testes but also in the adrenal glands and within the tumour tissue itself. Abiraterone blocks an enzyme called CYP17, which is needed at all three of these sources to make androgens, cutting off the tumour's hormone supply more completely than testosterone-suppressing injections alone.
Dosage & Administration
Standard dose: 1,000 mg (four 250 mg tablets, or two 500 mg tablets) taken orally once daily, together with prednisone 5 mg taken orally twice daily.
Condition-wise dose: Patients should also be on a GnRH analog (testosterone-suppressing injection) concurrently, or have had surgical removal of the testes.
Route: Oral, taken on an empty stomach; no food should be eaten for at least 2 hours before and 1 hour after the dose, as food substantially increases drug absorption.
Missed dose: Take the next dose at its scheduled time; don't double up.
Overdose: May worsen known side effects such as fluid retention, low potassium, or high blood pressure; requires medical attention.
Side Effects
Common: Fatigue, joint swelling or discomfort, fluid retention (swelling), hot flashes, diarrhoea, and high blood pressure.
Serious: Liver toxicity, adrenal insufficiency (especially if prednisone is stopped abruptly or during illness/stress), heart problems related to fluid retention and low potassium, and low blood sugar in diabetics.
Emergency symptoms: Yellowing of the skin/eyes, severe swelling, chest pain, irregular heartbeat, or signs of adrenal crisis (severe weakness, dizziness, vomiting).
Recovery advice: Prednisone is taken specifically to reduce the fluid retention and blood pressure effects of abiraterone; missing prednisone doses can allow these side effects to worsen, so it should not be stopped without medical advice.
Warnings & Precautions
Pregnancy: Not applicable (used only in men); contact with the tablets should be avoided by women who are or may become pregnant.
Breastfeeding: Not applicable.
Liver disease: Requires regular liver function monitoring; dose interruption or discontinuation needed if enzymes rise significantly; not recommended in severe pre-existing liver impairment.
Kidney disease: Used with caution; monitored for fluid retention and blood pressure effects.
Elderly: Commonly used in this age group, as prostate cancer is more common with age.
Children: Not applicable; a male-specific cancer medicine.
Drug Interactions
● CYP3A4 inducers (e.g., rifampin, phenytoin): can significantly reduce abiraterone levels; avoided or managed with dose adjustment.
● CYP2D6 substrates with a narrow therapeutic index (e.g., certain antidepressants, antiarrhythmics): abiraterone can increase their levels, requiring dose reduction of those medicines.
● Corticosteroids other than prednisone: dose adjustments may be needed if switching steroid type.
● Drugs affecting potassium levels (e.g., diuretics): combined use requires closer monitoring, given abiraterone's own effect on lowering potassium.
Monitoring Requirements
● Liver function tests before starting and regularly during treatment.
● Blood pressure checks.
● Serum potassium levels.
● Blood sugar monitoring in patients with diabetes.
Alternative Molecules
Enzalutamide, Apalutamide, Darolutamide (other hormonal therapies for advanced prostate cancer, different mechanism).
Combination Therapies
Always given together with prednisone (or prednisolone) to offset mineralocorticoid-related side effects, and alongside ongoing testosterone suppression (GnRH analog or surgical castration). Also approved in combination with olaparib for certain BRCA-mutated prostate cancers.
● Prostate Cancer Medicines
● Hormonal (Endocrine) Cancer Therapies
● CYP17 Inhibitors
FAQs
Q1.
It's used to treat advanced (metastatic) prostate cancer, both castration-resistant and high-risk castration-sensitive disease, always alongside prednisone.
Q2.
Prednisone offsets side effects like fluid retention, high blood pressure, and low potassium that abiraterone can otherwise cause.
Q3.
Food dramatically increases how much of the drug is absorbed, which can lead to overexposure and more side effects if taken with meals.
Q4.
No, it's a hormonal (endocrine) therapy that lowers androgen production, working differently from traditional chemotherapy.
Q5.
Regular liver function tests, blood pressure checks, and potassium level monitoring are standard throughout treatment.
References
Disclaimer
The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your oncologist to know if this treatment is appropriate for your condition.






